Low-dose irinotecan as a second-line chemotherapy for recurrent small cell lung cancer

18Citations
Citations of this article
32Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Objective: Irinotecan is a potent inhibitor of deoxyribonucleic acid topoisomerase 1 and the weekly schedule of 100-125 or 350 mg/m2 administration on Day 1 every 3 weeks is recommended for recurrent small cell lung cancer. However, severe gastrointestinal toxic effects and myelosuppression are often observed in this dose setting. We conducted a retrospective study to evaluate the efficacy and safety of low-dose irinotecan monotherapy (60 mg/m2 on Days 1, 8 and 15 every 4 weeks) as second-line chemotherapy for small cell lung cancer. Methods: The medical charts of small cell lung cancer patients who had received second-line chemotherapy at the National Cancer Center Hospital East between April 2003 and June 2012 were reviewed. Consecutive 57 patients who were treated with low dose of irinotecan (60 mg/m2 on Days 1, 8 and 15 every 4 weeks) were analyzed in this study. Results: Median age was 70 years (range, 51-83). Fifty-two (91%) were male, 36 (63%) had an Eastern Cooperative Oncology Group performance status 0-1 and 26 (46%) were sensitive relapse. The median number of chemotherapy cycles was 2. The objective response rate was 32% (95% confidence interval: 20-45%).The median progression-free survival and the median overall survival were 2.9 months (95% confidence interval: 1.9-3.4 months) and 5.3 months (95% confidence interval: 3.6-7.6 months), respectively. The incidence of Grade 3/4 neutropenia, diarrhea and nausea/vomiting was 21, 4 and 5%, respectively. Conclusions: Low-dose irinotecan monotherapy for recurrent small cell lung cancer might be effective with favorable toxicity. Randomized trial of 60 mg/m2 versus standard dose of irinotecan is warranted. © 2014. Published by Oxford University Press. All rights reserved.

Cite

CITATION STYLE

APA

Morise, M., Niho, S., Umemura, S., Matsumoto, S., Yoh, K., Goto, K., … Ohe, Y. (2014). Low-dose irinotecan as a second-line chemotherapy for recurrent small cell lung cancer. Japanese Journal of Clinical Oncology, 44(9), 846–851. https://doi.org/10.1093/jjco/hyu094

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free